10/09/2017 Guerbet to take part in the 65th edition of the Journées Francophones de Radiologie Diagnostique et Interventionnelle (JFR)
> Organization of two symposiums on October 13 and 14> Presentation of Vectorio®, an innovative medical device, at the “Interventional Radiology Village” Villepinte (France), October 9, 2017 (8:30 CEST) – Guerbet (FR0000032526 GBT), the global specialist in contrast products and solutions...
09/26/2017 2017 half-year results
> Satisfactory activity growth > Ebitda level above 15% Villepinte, September 26, 2017 - Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, has reported its consolidated half-year results, following the limited review by its...
CIRSE 2017 │ from September 16 to 20, 2017 │ Bella Center │ Copenhagen (Denmark)
09/14/2017 Guerbet Announces CE Mark for Vectorio®, An Innovative Medical Device for cTACE Procedures
Vectorio® will be presented at the upcoming radiology congresses
ESUR 2017 │ from September 14 to 17, 2017 │ Sheraton Sopot Hotel │ Sopot (Poland)
ESNR 2017 │ from September 14 to 17, 2017 │ Clarion Hotel Malmö Live │ Malmö (Sweden)
09/05/2017 FDA Approves Guerbet’s Dotarem® (gadoterate meglumine) for Pediatric Patients Younger than Two Years
Princeton (NJ, USA), September 5, 2017 – Guerbet LLC USA, the US affiliate of the global specialist in contrast products and solutions for medical imaging, announced today that the US Food and Drug Administration (FDA) has approved Dotarem® (gadoterate meglumine) for intravenous use with magnetic...